| Hartig Drug Company #24 | |
| 327 Main Street, Darlington, Wisconsin 53530 | |
| (608) 776-4481 |
| Name | Hartig Drug Company #24 |
|---|---|
| Organization Name | Hartig Drug Co Corp |
| Location | 327 Main Street, Darlington, Wisconsin 53530 |
| Type | Community/Retail Pharmacy |
| Phone | (608) 776-4481 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.
The Food and Drug Administration would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with the industry released by the agency on Friday.
Implants are usually the first choice for breast reconstruction after mastectomy. But when implant-based reconstruction fails, autologous reconstruction - using the patient's own tissues - is a safe procedure that improves patient outcomes, reports a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves.
› Verified 6 days ago
| NPI Number | 1316256431 |
| Organization Name | HARTIG DRUG CO CORP |
| Doing Business As | HARTIG DRUG CO. #24 |
| Type | Community/Retail Pharmacy |
| Address | 327 Main St, Darlington, WI 53530 |
| Phone Number | 608-776-4481 |
News Archive
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.
The Food and Drug Administration would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with the industry released by the agency on Friday.
Implants are usually the first choice for breast reconstruction after mastectomy. But when implant-based reconstruction fails, autologous reconstruction - using the patient's own tissues - is a safe procedure that improves patient outcomes, reports a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves.
› Verified 6 days ago
| NPI Number | 1902845381 |
| Organization Name | WHITFORD PHARMACY |
| Type | Community/Retail Pharmacy |
| Address | 327 Main St, Darlington, WI 53530 |
| Phone Number | 608-776-4481 |
News Archive
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.
The Food and Drug Administration would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with the industry released by the agency on Friday.
Implants are usually the first choice for breast reconstruction after mastectomy. But when implant-based reconstruction fails, autologous reconstruction - using the patient's own tissues - is a safe procedure that improves patient outcomes, reports a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves.
› Verified 6 days ago
News Archive
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.
The Food and Drug Administration would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with the industry released by the agency on Friday.
Implants are usually the first choice for breast reconstruction after mastectomy. But when implant-based reconstruction fails, autologous reconstruction - using the patient's own tissues - is a safe procedure that improves patient outcomes, reports a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
A multi-disciplinary team of Yale Cancer Center researchers has discovered a promising new method for delivering drugs into aggressive tumors by exploiting a unique feature of tumors themselves.
› Verified 6 days ago
Hartig Drug Company #24 Type: Community/Retail Pharmacy Location: 327 Main Street, Darlington, Wisconsin 53530 Phone: (608) 776-4481 |